ANSA.it Economia

OTEZLA reduced the number and pain of oral ulcers in the 12-week placebo-controlled Phase 3 RELIEF™ study

With this third indication in the U.S., OTEZLA is the first and only treatment approved for oral ulcers associated with Behçet’s Disease

• L'elenco dei farmaci essenziali è focalizzato sul tumore e altre emergenze sanitarie globali, con una particolare enfasi sulla raccomandazione di soluzioni efficaci, la determinazione intelligente delle priorità e l'accesso ottimale per i pazienti¹

• Utile registrato a livello mondiale pari a 8,3 miliardi di dollari, ossia un aumento del 5% in termini sequenziali
• Utile registrato a livello internazionale pari a 5,5 miliardi di dollari, ossia un aumento dell’8% in termini sequenziali
• Utile registrato nel Nord America pari a 2,8 miliardi di dollari, ossia un aumento del 2% in termini sequenziali
• Reddito d’esercizio al lordo delle imposte a livello di segmento pari a 968 milioni di dollari, ossia un aumento del 7% in termini sequenziali
• Rendimento per azione pari a $0,35
• Flusso di cassa generato dalle operazioni e flusso di cassa libero rispettivamente pari a 1,1 e 0,5 miliardi di dollari
• Approvato un dividendo trimestrale in contanti di $0,50 dollari per azione

• The Essential Medicines List focuses on cancer and other global health challenges, with an emphasis on recommending effective solutions, smart prioritisation, and optimal access for patients¹

Mark G. Papa sarà Presidente del Consiglio d’Amministrazione

• Worldwide revenue of $8.3 billion increased 5% sequentially
• International revenue of $5.5 billion increased 8% sequentially
• North America revenue of $2.8 billion increased 2% sequentially
• Pretax segment operating income of $968 million increased 7% sequentially
• EPS was $0.35
• Cash flow from operations and free cash flow were $1.1 billion and $0.5 billion, respectively
• Quarterly cash dividend of $0.50 per share was approved

Mark G. Papa to Become Chairman of the Board

• Group revenue up 15.9%; order intake up 18.7%; earnings margin 26.6%
• High growth dynamics in the Bioprocess Solutions Division; moderate development of the Lab Products & Services Division
• Guidance for 2019 raised

Il nuovo esclusivo nome del marchio combina i termini giapponese e greco corrispondenti rispettivamente a “memoria” e “valore”

• Boehringer Ingelheim has entered into a collaboration and global license agreement for Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 to be developed for fibrosing interstitial lung diseases including IPF

• With this new partnership Boehringer Ingelheim further expands its commitment to bring new treatments to patients with fibrosing interstitial lung diseases including IPF

• Bridge Biotherapeutics stands to receive up to more than EUR 1.1 billion assuming all milestones are met

Based on the latest mobile DRAM standard, the new Samsung 12Gb LPDDR5 maximizes the potential of 5G and AI features in future flagships

Patient-reported data will help inform research in rare form of eye cancer